Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa
Yoel Lubell, Arthorn Riewpaiboon, Arjen M Dondorp, Lorenz von Seidlein, Olugbenga A Mokuolu, Margaret Nansumba, Samwel Gesase, Alison Kent, George Mtove, Rasaq Olaosebikan, Wirichada Pan Ngum, Caterina I Fanello, Ilse Hendriksen, Nicholas PJ Day, Nicholas J White & Shunmay Yeung
Volume 89, Number 7, July 2011, 504-512
Table 5. Costa per disability-adjusted life year (DALY) averted and cost per death averted in each of the study sites
|Parameter||United Republic of Tanzania
||Mbarara, Uganda||Ilorin, Nigeria||All sites|
|Mean incremental cost per patient treated with artesunate||1.2||−1.6||1.0||22.5||3.0|
|Mean DALYs averted with artesunate||0.7 (pooled data from all trial sites)|
|NNTb to avert 1 death||41 (pooled data from all trial sites)|
NNT, number needed to treat.
a All costs in United States dollars.
b This represents the number of patients one would need to treat with artesunate instead of quinine to avert 1 death.